Cargando…

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

INTRODUCTION: As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread, several variants have emerged. Variants B.1.1.7 and B.1.351 have attracted significant attention owing to their widespread transmission and possible immune evasion. A total of 19 SA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Lianlian, Gao, Fan, Zhang, Jialu, He, Qian, Mao, Qunying, Xu, Miao, Liang, Zhenglun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054487/ https://www.ncbi.nlm.nih.gov/pubmed/33851875 http://dx.doi.org/10.1080/14760584.2021.1903879

Ejemplares similares

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine
por: Gao, Fan, et al.
Publicado: (2022)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content
por: Han, Lu, et al.
Publicado: (2022)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
por: Liu, Dong, et al.
Publicado: (2022)

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
por: Liu, Pei, et al.
Publicado: (2021)

A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I
por: Song, Ziyang, et al.
Publicado: (2022)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
por: Chen, Pan, et al.
Publicado: (2016)

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

A cross-sectional seroepidemiology study of EV-D68 in China
por: Sun, Shiyang, et al.
Publicado: (2018)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Research progress on circular RNA vaccines
por: Bai, Yu, et al.
Publicado: (2023)

Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains
por: Huo, Yaqian, et al.
Publicado: (2021)

A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5
por: Mao, Qunying, et al.
Publicado: (2018)

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC
por: Liang, Zhenglun, et al.
Publicado: (2014)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

SARS-CoV-2 vaccination efficacy on hospitalisation and variants
por: Rozencwajg, Sacha, et al.
Publicado: (2021)

SARS-CoV-2 vaccination efficacy on hospitalisation and variants
por: Rozencwajg, Sacha, et al.
Publicado: (2021)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Research Advances on the Stability of mRNA Vaccines
por: Cheng, Feiran, et al.
Publicado: (2023)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

SARS-CoV-2 Variants and Vaccines
por: Krause, Philip R., et al.
Publicado: (2021)

COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
por: Stefanelli, Paola, et al.
Publicado: (2022)

Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants
por: Zhang, Jianzhong, et al.
Publicado: (2023)

The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China
por: Zhang, Xi-Ru, et al.
Publicado: (2023)

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
por: Rayati Damavandi, Amirmasoud, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
por: Sharun, Khan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fug6hl3f6069clk0uk2c2ablbi